Global PARP Inhibitors Market by Product
Global PARP Inhibitors Market by Indication
Global PARP Inhibitors Market Based on Region
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitors Market Snapshot
Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Technology Advancement in PARP Inhibitors
4.10. Key Trends in the Market
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Niraparib (Zejula)
5.2.2. Olaparib (Lynparza)
5.2.3. Rucaparib (Rubraca)
5.2.4. Talazoparib (Talzenna)
5.2.5. Veliparib
5.2.6. Other Pipeline Drugs
Chapter 6. PARP Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis
6.1. Indication Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Ovarian Cancer
6.2.2. Breast cancer
6.2.3. Prostate and Pancreatic Cancer
Chapter 7. PARP Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by product, 2021-2034
7.1.2. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by indication, 2021-2034
7.1.3. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034
7.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034
7.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034
7.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034
7.3.3. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million)
7.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million)
7.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5. MEA
7.5.1. MEA revenue PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million) 2021-2034
7.5.2. MEA revenue PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million) 2021-2034
7.5.3. MEA revenue PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1 Johnson & Johnson Services, Inc.
8.2.2 Merck KGaA
8.2.3 GSK plc.
8.2.4 Pfizer Inc.
8.2.5 AbbVie Inc.
8.2.6 Teva Pharmaceutical Industries Ltd.
8.2.7 Artios Pharma
8.2.8 Genentech, Inc.
8.2.9 Karyopharm Therapeutics Inc.
8.2.10 Repare Therapeutics Inc
8.2.11 ONO PHARMACEUTICAL CO., LTD
8.2.12 Jiangsu Hengrui Pharma Co., Ltd.
8.2.13 Bristol-Myers Squibb Co
8.2.14 AstraZeneca plc
8.2.15 Checkpoint Therapeutics, Inc.
8.2.16 Eisai Co., Ltd.
8.2.17 IMPACT Therapeutics
8.2.18 JEIL PHARMA CO.,LTD.
8.2.19 Kyowa Kirin Co., Ltd
8.2.20 SyntheX
8.2.28. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.